EFFECTIVENESS AND SAFETY OF FILGRASTIM BIOANALOGUE IN TREATMENT AND PROPHYLAXIS OF GRANULOCYTOPENIA IN CHILDREN

Abstract

The article presents results of a study of tolerability of recombinant human granulocyte colony-stimulating factor (G-CSF) Leukostim and its efficacy compared to Neupogen in patients with neutropenia, associated with chemotherapy of malignant tumors in children. At the 1^st stage (randomized double-blinded study of tolerability) 10 patients randomly received injections of Leukostim or Neupogen for treatment of neutropenia. Intensity of pain was estimated by visual analogue scale. Both medications were well-tolerated: an average pain intensity was 1,1 for Leukostim and 1,7 for Neupogen. At the 2nd stage of the study courses of different G-CSF drugs (5 mсg/kg daily) were administrated subsequently to 40 patients with malignant tumors treated with repeated identical blocks of chemotherapy. The time of neutropenia correction and absolute increase of neutrophil count were similar for both medications. Thus, Leukostim and Neupogen have identical tolerability and efficacy in patients with neutropenia associated with chemotherapy of malignant tumors.

Key words: children, neutropenia, chemotherapy of malignant tumors, granulocyte colony-stimulating factor, filgrastim, visual analogue scale of pain.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(1):18-25)